Gayatri Digambar: Safe Anticoagulation Conversion
Gayatri Digambar, B.Pharm Finalist and Registered Pharmacist, posted on LinkedIn:
”Anticoagulation Conversion
Mastering the Transition: Ensuring Patient Safety in Complex Drug Therapy
As Registered Pharmacists, managing anticoagulation therapy transitions (bridging) is one of our most critical clinical responsibilities. The precision of these conversions directly impacts patient outcomes and minimizes the risk of bleeding or clotting.
Sharing a look at the key protocols for safely converting between different anticoagulants:
Bridging from Heparin/LMWH to Warfarin: This requires a careful overlap period until the INR is consistently in the therapeutic range (>2 for at least 2 days).
Transitioning to DOACs (Dabigatran, Rivaroxaban, Apixaban): Exact timing is crucial. For instance, stop IV heparin immediately and start the DOAC within 0–2 hours of the next scheduled LMWH dose to maintain anticoagulation continuity.
Warfarin Management: When switching from warfarin to a DOAC, the INR must be checked and confirmed to be <2 before initiating the new agent.
This attention to detail is vital for clinical excellence and regulatory compliance.”
Stay updated with Hemostasis Today.
-
Apr 12, 2026, 22:12Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management
-
Apr 12, 2026, 21:24Heghine Khachatryan: Diagnosing PNH in Resource-Limited Settings
-
Apr 12, 2026, 21:15Katariina Öörni: Role of Cholesterol Absorption Efficiency in Atherosclerosis
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes